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ABSTRACT
Multiple myeloma is a blood dyscrasias that accounts of almost 10% of all hematological malignancy. The presentation 
of myeloma kidney is highly variable and it often presents as renal insufficiency, renal tubular dysfunction and 
proteinuria of various types. In Malaysia the true incidence of myeloma kidney is unknown. Often the diagnosis of 
myeloma kidney was missed out despite the patient has sought medical treatment early. A high index of suspicion is 
required when the middle to elderly age patients present with unexplained renal impairment and enlarged kidneys. 
We present here the presentation of a rare subtype of myeloma in a relatively young patient whereby the patient 
presented with nephrotic syndrome and azotemia.
Keywords: Ig D Multiple myeloma, Amyloidosis, Cast nephropathy
Corresponding Author:
Assoc. Prof. Dr. Christopher Lim
Tel: +6-03-89472568
E-mail: drchrislim@gmail.com
INTRODUCTION
Multiple myeloma (MM) is not a common cancer in 
those below 50 years of age. The trade mark of MM 
is overproduction of monoclonal immunoglobulin 
or light chains which are filtered by glomeruli. These 
light chains when mixed with the renal parenchymal 
tissue are highly nephrotoxic.  Others mechanism of 
renal injury include production of  myeloma casts, 
amyloid deposition, hypercalcemia, hyperuricemia and 
nephrotoxic agents such as non-steroidal inflammatory 
drugs or contrast agent for imaging. Often the injury 
occurs as a combination of insults. Prompt detection 
and referral to both nephrologist and hematologist are 
crucial to ensure an excellent renal prognosis and life 
expectancy.
CASE REPORT
A 47-year-old lady was referred from a secondary hospital 
for assessment of advanced renal impairment. She gave 
a history of progressive weakness, itchiness, nausea and 
breathlessness for 8 months. Her past medical history 
includes hypertension of 5 years duration in which 
she was prescribed perindopril 4mg once a day by her 
family doctor.  She was also told to have normochromic 
normocytic anemia and was advised blood transfusion 
for which she refused. No work up of anemia was ever 
done. On further questioning, she admitted that she has 
polyuria which was bothering her. She does not have any 
back pain or history of fracture. Physical examination 
revealed a normotensive state with a blood pressure of 
139/73mmHg and pulse rate of 86/min. She appeared to 
be in pale and sallow looking. Cardiovascular, abdomen 
and respiratory examinations were unremarkable. 
Investigations revealed: Urine protein: 4+, urine RBC: 
5/hpf, serum total protein: 71 g/L, serum albumin: 27 
g/L, alkaline phosphatase: 85 U/L,globulin: 44 g/L ; 
urea: 27 µmol/l, sodium: 135 mmol/l, potassium: 5.4 
mmol/l , creatinine: 1252 µmol/l ; calcium: 1.97 mmol/l, 
phosphate: 3.96 mmol/l; total white: 5.2 X 109/L, 
hemoglobin: 5.7 g/dL, platelet: 282 x 109 /L; erythrocyte 
sedimentation rate (ESR): 124 mm/hour and 24 hours 
urine protein: 17.85g. Her antinuclear antibody and 
complements were normal. Renal ultrasound showed 
raised echogenicity with bipolar length of right 
kidney and left kidney measures 13.9cm and 12.9 cm 
respectively. There was no feature of amyloid related 
complications noted. In view of bilateral large kidneys 
with an unknown cause of renal impairment, a renal 
biopsy was carried out.  Renal biopsy revealed features 
in keeping with myeloma cast nephropathy, moderate 
to severe chronic tubule-interstitial changes with 
concurrent peritubular amyloid deposition (Figures1,2). 
Serum protein electrophoresis revealed Immunoglobulin 
D with Lambda light chains at 14.6 g/L. Skeletal survey 
revealed lytic lesions in spine, ribs, pelvic and femur 
bones. Bone marrow aspiration and biopsy showed 
diluted sample with scattered plasma cells. A diagnosis 
of Immunoglobulin D multiple myeloma (Ig D MM) 
was made. She was referred to hematologist for further 
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treatment. A permanent catheter was inserted and she 
received regular hemodialysis three times per week. 
Unfortunately, her renal function did not recover despite 
receiving full dose of chemotherapy which consisted of 
bortezomib, cyclophosphamide, dexamethasone and 
thalidomide. She had a relapsed of multiple myeloma 
4 months after remission (undetectable band in 
electrophoresis) and succumbed due to acute coronary 
syndrome a few months down the road.
DISCUSSION
The incidence of MM in Malaysia ranges from 0.4 to 0.7 
per 100,000 people. The incidence ranges from 0.5 per 
100,000 people for those 15 - 49 year of age to 2.6 – 3.3 
per 100,000 people for those 50-60 year of age. The 
incidence is highest in those over 70 year of age where 
it is 1.8 – 5 per 100,000 people (1). The exact incidence 
of myeloma kidney in Malaysia is unknown. The relative 
young age of our patient may have contributed to the 
delayed diagnosis of her condition. 
Renal disease in myeloma most often presents as renal 
impairment and proteinuria. Severe renal impairment 
is expected in one fifth of the cases (2).  Proteinuria is 
observed in over 80% of cases and it consists mostly 
of light chains. Light-chain proteinuria can be massive 
(> 10 g/d) but yet cannot be detected by conventional 
dipstick or urinalysis. Fewer than 15 to 25% of patients 
with myeloma actually develop the classical nephrotic 
syndrome with conventional albuminuria. This often 
is the results of amyloid deposition or monoclonal Ig 
G deposition disease (MIDD). The renal pathology of 
myeloma cast nephropathy, MIDD and amyloidosis 
is complex and diverse. However in each occasion, it 
is preceded by the production in the bone marrow of 
an abnormal immunoglobulin fragment (usually a light 
chain) by a clone of neoplastic plasma cells. Other 
causes that can contribute to the renal impairment 
include obstructive uropathy, hyperviscocity syndrome, 
hyperuriceamia, volume depletion and the use 
of nephrotoxic agents such as non-steroidal anti-
inflammatory drugs or contrast agents. A kidney biopsy 
is required to establish the diagnosis.
Our patient suffered from IgD MM which is an 
extremely rare form of MM. It accounts for almost 2% 
of all myeloma cases (3).  It is associated with extremely 
advanced disease at diagnosis, an increased frequency 
of undetectable or small monoclonal (M)-protein levels 
on electrophoresis; osteolytic lesions; extramedullary 
involvement; amyloidosis; a lambda light chain 
predilection; renal impairment and hypercalcemia. 
Fig. 1. Masson trichrome statining showing non-polarizing crystals inside the tubules
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Although survival of patients with IgD MM or IgE MM is 
shorter in comparison to those with immunoglobulin G 
(IgG) MM or immunoglobulin A (IgA) MM, the outcome 
for patients with IgD and IgE subtypes is improving with 
the use of novel agents and autologous transplantation 
(3).  Unfortunately our patient however has declined 
autologous transplantation when offered by the 
hematologist. Her outcome was guarded in view of the 
advance renal impairment, low hemoglobin level level 
and multiple areas of the bone destroyed by the cancer.
The management of myeloma kidney involves anti-
myeloma therapy with bortezomib based chemotherapy 
with high dose dexamethasone (4).   Chemotherapy 
should be initiated as rapidly as possible to decrease 
light chain production.  All potentially nephrotoxic 
agents should be discontinued. Unless contraindicated, 
intravenous fluid therapy with the goal of attaining 
a positive daily urine output of at least three liters, 
should be provided to all patients to reduce light chain 
precipitation, hypercalcemia and hyperuricemia. 
Dialysis should be initiated as per normal indications 
while the use of extracorporeal methods remains 
controversial.
The case highlighted the importance of being vigilance 
in cases of acute renal impairment of unknown origin 
with enlarged kidneys as myeloma kidney remains a 
distinct possibility. Prompt detection and referral to both 
nephrology and hematologist are crucial to ensure an 
excellent renal prognosis and life expectancy.
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Fig. 2. Hematoxylin and eosin stain showing tubules show irregularly fragmented cast with cellular debris 
admixed with red cell cast

